Blueprint Medicines Corp Logo Image

Blueprint Medicines Corp

Blueprint Medicines Corp Banner Image

Most Recent Annual Report

2019 Annual Report and Form 10K

Blueprint Medicines Corp

Blueprint Medicines Corp does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Blueprint Medicines Corp

201-500 Employees
Based in Cambridge, Massachusetts

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4.

Ticker:
BPMC
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol

Filter by: